Cyclobenzaprine Alternatives Compared
| Cyclobenzaprine | Ubrelvy (ubrogepant) | Erenumab |
|
|---|
| Cyclobenzaprine | Ubrelvy (ubrogepant) | Erenumab |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Cyclobenzaprine is a muscle relaxant that may be used short-term to treat muscle spasms caused by musculoskeletal conditions, in addition to rest and physical therapy. Sedation is a common side... View more |
Prescription only
Ubrelvy is a prescription medicine that may be used to treat acute migraine attacks in adults and works by blocking the effects of a protein, called CGRP that is thought to play a role in migraine... View more |
Prescription only
Prescribed for Migraine Prevention, Headache, Migraine. Erenumab may also be used for purposes not listed in this medication guide. |
Related suggestions |
|||||||||||||||
| More about Cyclobenzaprine | More about Ubrelvy (ubrogepant) | More about Erenumab | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Cyclobenzaprine has an average rating of 6.0 out of 10 from a total of 615 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 30% reported a negative effect. |
Ubrelvy has an average rating of 6.2 out of 10 from a total of 249 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 38% reported a negative effect. |
Erenumab has an average rating of 5.2 out of 10 from a total of 640 ratings on Drugs.com. 38% of reviewers reported a positive effect, while 43% reported a negative effect. |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Side Effects | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
Lower cost generic |
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Cyclobenzaprine prices |
View all Ubrelvy prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||
|
|
N/A |
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Amrix, Comfort Pac with Cyclobenzaprine |
N/A |
Aimovig | ||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
|
72 hours |
7 hours |
672 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 444 drugs are known to interact with Cyclobenzaprine:
|
A total of 224 drugs are known to interact with Ubrelvy:
|
A total of 2 drugs are known to interact with Erenumab:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
August 26, 1977 |
December 23, 2019 |
N/A |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.